In order to develop the petropharmaceutical chain, Kimia Group began operating a semi-finished drug line in Kaveh Industrial Park.
Kimia Group, with thirty years of experience, produces a wide range of petrochemical, chemical, and pharmaceutical products as feedstock for 20 active industries in the country.
Kimia Group has developed an integrated approach to transforming its petrochemical capacities into high-value-added pharmaceutical products by designing a Petrochemical to Pharmaceutical (P2P) strategy. This strategy forms a coherent chain from the production of basic chemicals to the final production of drugs within the group.
Today, the P2P strategy, as one of the main pillars of Kimia Group’s growth, has paved the way for the development of strategic products, promoting self-sufficiency, and strengthening the group’s presence in regional and global markets.
Apira Pharma Company, as one of the subsidiaries of Kimia Group, was established in Kaveh Industrial City with the aim of producing semi-finished pharmaceutical products to connect the production cycle of active pharmaceutical ingredients to the production cycle of final drugs with a production capacity of 500 types of pellets and DC.
Also, the production unit for the active ingredient of metformin with an annual capacity of 1,000 tons per year was put into operation today at Kimiagaran Chemical Industries Company in Shazand, Arak. At the end of this ceremony, a production line for various narcotic syrups with a capacity of 10 million bottles per year was inaugurated at Parand Daru Pharmaceutical Company, another subsidiary of Kimia Group located in Kaveh Industrial City.